Abstracts tagged "juvenile myositis and myopathy"

Abstract Number: 86 • 2017 Pediatric Rheumatology Symposium
The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies
Takako Miyamae, Takayuki Kishi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Demographics,clinical features,and outcomes among myositis-specific autoantibody (MSA) and myositis-associated autoantibodies (MAAs) subgroups were assessed in children with juvenile idiopathic inflammatory myopathies (JIIM). Methods: MSAs…
Abstract Number: 281 • 2016 ACR/ARHP Annual Meeting
Characterization of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies
Takayuki Kishi¹, Andrew Mammen^2,3, Katherine Pak², Lilliana Barillas-Arias⁴, Michael Henrickson⁵, Paul L. McCarthy⁶, Bracha Shaham⁷, Pamela F. Weiss⁸, Iren Horkayne-Szakaly⁹, Frederick W. Miller¹⁰, Lisa G. Rider¹⁰ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ⁴Bernard & Millie Duker Children's Hospital, Albany Medical Center, Albany, NY, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics, Yale University School of Medicine, New Haven, CT, ⁷Pediatric Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁸Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁹Joint Pathology Center, Defense Health Agency, Silver Spring, MD, ¹⁰Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies (Abs) to 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (HMGCR) identified in adult myositis patients with immune-mediated necrotizing myopathies (IMNM) have been associated with severe weakness,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].